BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19397219)

  • 21. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
    Weinberger MH; Glazer RD; Crikelair NA; Chiang YT
    J Hum Hypertens; 2010 Dec; 24(12):823-30. PubMed ID: 20182456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
    Weir MR; Neutel JM; Bhaumik A; De Obaldia ME; Lapuerta P
    J Clin Hypertens (Greenwich); 2007 Dec; 9(12 Suppl 5):23-30. PubMed ID: 18046109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
    Howe P; Phillips P; Saini R; Kassler-Taub K
    Clin Exp Hypertens; 1999 Nov; 21(8):1373-96. PubMed ID: 10574419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
    Al Balushi KA; Habib JQ; Al-Zakwani I
    Med Princ Pract; 2013; 22(3):265-9. PubMed ID: 23235349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
    Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
    Agabiti-Rosei E; Manolis A; Zava D; Omboni S;
    Adv Ther; 2014 Feb; 31(2):217-33. PubMed ID: 24415271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study.
    Grassi G; Seravalle G; Brambilla G; Dell'Oro R; Trevano FQ; Fici F; van Bortel L; Mancia G
    Adv Ther; 2017 Jan; 33(12):2173-2187. PubMed ID: 27771847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
    Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
    Neutel JM; Smith D
    J Int Med Res; 2005; 33(6):620-31. PubMed ID: 16372579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
    Tschöpe C; Tschöpe R; Unger T
    MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.